Can the challenges of  lipid purification be overcome for next-generation therapeutics?

Lipid nanoparticles (LNPs) are at the forefront of modern drug delivery, playing a key role in mRNA vaccines and gene therapy products. Their formulations are built from four critical lipid components: a PEG-conjugated lipid that enhances particle stability, an ionizable cationic lipid that enables cellular uptake and endosomal escape, a structural lipid that stabilizes the bilayer, and cholesterol, which modulates membrane fluidity and integrity.

During synthetic production, these lipids often contain structurally similar and chemically labile impurities, including unreacted starting materials, over-alkylated derivatives, or degradation products. Such impurities are especially challenging to remove with conventional solid-phase chromatography, which can cause sample loss or degradation — particularly for ionizable and PEGylated lipids. Effective purification is therefore essential to ensure the stability, safety, and performance of LNP-based therapeutics.

We have prepared a detailed application note that you can download, presenting real-world case studies on how Centrifugal Partition Chromatography (CPC) addresses these challenges. By eliminating the need for a solid stationary phase and using optimized biphasic solvent systems with advanced elution modes, CPC enables the gentle yet efficient purification of key LNP components — including DMG-PEG 2000, ALC-0315, 19B28, and 23B1. This approach improves yield, minimizes degradation, and supports robust, scalable lipid manufacturing for therapeutic applications.

Benefits of CPC

Gentle purification for chemically labile lipids

Ionizable, PEGylated, and amphipathic lipids used in LNP formulations are often unstable under conventional solid-phase chromatography. CPC operates without a solid stationary phase, eliminating irreversible adsorption and significantly reducing the risk of degradation for sensitive lipid molecules.

High selectivity for structurally similar impurities

Synthetic lipid production frequently generates closely related by-products with similar polarity and partition behavior. CPC leverages tunable biphasic solvent systems and partition-based separation to resolve these challenging impurities with high purity, even when conventional methods fail.

Scalable performance from laboratory to production

CPC enables reproducible purification from gram-scale laboratory development to preparative and industrial-scale manufacturing. The technology supports high sample loading, predictable scale-up, and robust operation across different lipid classes critical for LNP formulations.

Proven results for key LNP lipid components

This application note demonstrates successful CPC purification of essential LNP lipids, including DMG-PEG 2000, ALC-0315, 19B28, and 23B1, achieving high purity and yield while improving overall process robustness for therapeutic nanoparticle manufacturing.